Join the Oncology Voice Network. Join for Free
Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
Cancer drug pricing Cancer care costs Cancer drug efficacy Progression-free survival Value-based pricing in oncology FDA anticancer approvals

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020


Share This Article


Summary

  • The US has worse cancer-related outcomes compared to other high-income countries and has the highest cost of cancer care globally.
  • High costs may be attributed to the improved efficacy of expensive new cancer drugs, though the relationship between cost and benefit is debated.
  • A study found a link between drug price and measures of benefit, equating progression-free survival (PFS) with overall survival (OS), which is controversial due to unclear health benefits of PFS.
  • Another study found no link between drug efficacy and pricing for cancer drugs approved between 2009 and 2013.
  • In the past five years, there has been an increase in cancer therapies and a focus on value-based pricing, questioning whether newer drugs offer better benefits to justify higher costs.
  • The study aims to analyze recent FDA anticancer drug approvals to assess the relationship between cost and efficacy.

The US has worse cancer-related outcomes than other high-income countries while bearing the highest cost of cancer care in the world. A reason for increasing cost may be improved efficacy of expensive novel agents. One study found an association between measures of benefit and price, although the study considered gains in progression-free survival (PFS) to be the same as gains in overall survival (OS), an assumption that may be debated, given the uncertainty regarding health benefits associated with PFS. Another study of all cancer drug approvals from 2009 to 2013 found no association between measures of efficacy and pricing of cancer drugs.

The past 5 years have seen a marked increase in the number of cancer therapies on the market and a greater interest in value-based pricing. It is unclear whether the value proposition has shifted: have cancer drugs started to rely on improved benefit and decreased use of surrogate end points to justify skyrocketing costs? We described these trends by estimating all US Food and Drug Administration (FDA) anticancer approvals in recent years and evaluating if an association exists between their cost and efficacy.

Click for Source Download PDF version
Cancer drug pricing, Cancer care costs, Cancer drug efficacy, Progression-free survival, Value-based pricing in oncology, FDA anticancer approvals

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
OVN Avatar Natansh D. Modi, BPharm; Ahmad Y. Abuhelwa, PhD; Ross A. McKinnon, PhD

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Explore OVN